drugset / Trial / NCT02779777
Tipifarnib in Subjects With Myelodysplastic Syndromes
RandomizedSingle-groupSingle-blindTreatment
Summary
This is a Phase 2 randomized, open-label, two-stage study designed to investigate the antitumor activity of tipifarnib in approximately 36 eligible subjects with MDS who have no known curative treatment. Subjects will be randomized to receive tipifarnib orally with food according to one of 2 treatment regimens.
Timeline
- Start
- 2016-06-01
- Primary completion
- 2018-08-28
- Completion
- 2018-08-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tipifarnib | Small molecule | 300 mg | Oral |
| Subject | tipifarnib | Small molecule | 600 mg | Oral |